Hympavzi is a medicine used to prevent bleeding episodes in patients aged 12 years and above weighing at least 35 kg with severe haemophilia A or B. Haemophilia A and B are inherited bleeding disorders caused by the lack of factor VIII (for haemophilia A) or factor IX (for haemophilia B), which are proteins needed to produce blood clots to stop bleeding. Hympavzi is used in people who have not developed inhibitors (proteins made by the body’s natural defenses) against factor VIII or factor IX. Hympavzi contains the active substance marstacimab.
Therapeutic Indication
### Therapeutic indication Hympavzi is indicated for routine prophylaxis of bleeding episodes in patients 12 years of age and older, weighing at least 35 kg, with: - severe haemophilia A (congenital factor VIII deficiency, FVIII < 1%) without factor VIII inhibitors, or - severe haemophilia B (congenital factor IX deficiency, FIX < 1%) without factor IX inhibitors.
Therapeutic Area (MeSH)
ATC Code
B02BX11
ATC Item
xb 02 bx 11
Pharmacotherapeutic Group
Antihemorrhagics
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| marstacimab | N/A | Marstacimab |
EMA Name
Hympavzi
Medicine Name
Hympavzi
Aliases
N/ANo risk management plan link.
